Anti‐epidermal or anti‐vascular endothelial growth factor as first‐line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients

摘要: Background In metastatic colorectal cancer, the modified Glasgow prognostic score (mGPS) has been approved as an independent indicator of survival. No data existed on poor prognosis patients treated with molecular-targeted agents. Methods From January 2007 to February 2012, cancer and predictive survival (mGPS = 2), 5-fluorouracil-based chemotherapy in addition anti-epidermal growth factor receptor (EGFR) or anti-vascular epidermal (VEGF) therapy, were included assess interest targeted therapy within mGPS = 2' patients. Results A total 27 received a systemic anti-EGFR treatment (cetuximab; n = 18) anti-VEGF (bevacizumab; n = 9). Median follow-up was 12.1 months (interquartile range 4.9–22). Patients Eastern Cooperative Oncology Group (ECOG) Performance Status 1, 2, 3 66% (n = 18), 26% (n = 7), 8% (n = 2), respectively. Comparing groups, median progression-free 3.9 15.4 months, respectively, significantly different (P = 0.046). Conversely, overall not between two groups (P = 0.15). Conclusion Our study confirmed mGPS = 2 despite use identified superiority survival, without significant benefit compared therapy. Our results deserved confirmation by prospective clinical trial.